1. Home
  2. VRTX

as 10-23-2025 3:50pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Technology

EDP Services

Nasdaq

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Founded: 1989 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 96.6B IPO Year: 1991
Target Price: $491.78 AVG Volume (30 days): 1.4M
Analyst Decision: Buy Number of Analysts: 26
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 14.07 EPS Growth: N/A
52 Week Low/High: $362.50 - $519.88 Next Earning Date: 11-03-2025
Revenue: $11,418,800,000 Revenue Growth: 10.46%
Revenue Growth (this year): 10.92% Revenue Growth (next year): 9.55%

VRTX Daily Stock ML Predictions

Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Biller Jonathan VRTX EVP and Chief Legal Officer Oct 2 '25 Sell $404.21 694 $280,521.74 15,653

Share on Social Networks: